FDA recalls Pain Wizard topical pain relief for ingredient specification issues
ARG Laboratories recalled Pain Wizard topical pain relief roll-on due to active ingredient out of specification and violative-grade propylene glycol used in manufacturing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The recall is for manufacturing specification violations (out-of-spec active ingredients and violative-grade propylene glycol), which represents a quality control concern rather than a documented safety hazard. This is a precautionary recall for ingredient quality standards.
Plain-English summary
Pain Wizard Natural Relief for Muscular & Arthritic Pain is being recalled by ARG Laboratories, Inc. The affected product is a 3 fl oz topical roll-on (lot 17323C3, expiration 06/30/2025), distributed nationwide in the USA.
The FDA classified this as a Class II recall due to manufacturing specification violations. The product's active ingredients are out of specification, and a violative-grade propylene glycol was used in manufacturing. Propylene glycol that is violative-grade does not meet FDA standards for pharmaceutical use.
Consumers who have purchased this product should discontinue use. No illnesses or injuries have been reported.
The recalled product
- Product
- Pain Wizard, Natural Relief for Muscular & Arthritic Pain, (Camphor 3%, Menthol 3%), Enriched with Capsaicin, Camphor, Menthol & MSM, Roll-On 3 fl oz (88.7ml), painwizard.com Made in the USA, PO Box 1099, Johnstown, CO 80534, UPC 8 63865 00010 9
- Manufacturer
- ARG Laboratories, Inc.
- Category
- Drug — Topical OTC Pain Relief
- Hazard
- ingredient-specification-violation
- manufacturing-quality-issue
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 17323C3
- Exp 06/30/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27